ASH 2025 Successfully Concludes | Kindstar Global Showcases Cutting-Edge Achievements in Orlando, Charting a New Blueprint for Hematology

The 67th American Society of Hematology (ASH) Annual Meeting (ASH 2025) successfully concluded from December 6 to 9 in Orlando, USA. As one of the most influential academic events in the global hematology field, ASH brought together experts, scholars, innovative enterprises, and clinical practitioners from around the world to discuss cutting-edge science, clinical treatments, and technological breakthroughs in blood diseases.

Kangsheng Global Medical Specialized Testing Group, a leading specialized testing group in China with over two decades of expertise in hematology diagnostics, has once again taken the global stage.At booth 1181, we engaged in profound and fruitful exchanges with global peers, comprehensively showcasing our comprehensive capabilities in precision diagnostics for hematological malignancies, companion diagnostic collaborations, central laboratory services, and cutting-edge technology research and development.

On-site Report: Captivating global attention with vibrant and dynamic exchanges.

During the conference, the Kindstar Global booth attracted a large number of international visitors, fostering lively interactions. We held in-depth discussions with top experts and scholars, pharmaceutical R&D leaders, biotechnology companies, and CRO representatives from North America, Europe, Asia, and other regions on hot topics such as CAR-T therapy optimization, CRISPR gene-editing applications, MRD (minimal residual disease) monitoring, and standardization of molecular diagnostics for hematological malignancies.

Business Focus：Global presentation of professional platforms and technical services.

Haixi Biotech: Focused on Molecular Diagnostics for Hematological Malignancies

Our specialized technical platform, Haixi Biotech, prominently showcased its complete product portfolio in fusion gene detection, targeted gene panels, and automated bioinformatics analysis. By delivering tool-based, standardized, and automated solutions, we are committed to providing globally consistent and highly reliable test results, gaining widespread attention and recognition from international peers and laying a solid foundation for future international cooperation.

CRO and Global Collaboration: Facilitating the Implementation of Innovative Outcomes

Leveraging our core competencies in companion diagnostics (CDx) development, central laboratory testing, and clinical translation in China, KSL Biomedical established direct communication channels with several globally renowned pharmaceutical companies and innovative biotech firms during the conference. We are dedicated to building an efficient international collaboration network to accelerate the introduction and application of cutting-edge therapies and diagnostic technologies in the Chinese market.

Voice of Research：Research findings selected for poster presentation, highlighting scientific research capabilities.

At this year's ASH conference, several research achievements from KSY Global’s collaborative projects were selected for poster presentations, showcasing our depth of scientific research and clinical value in the field of precision medicine for hematological tumors.

Poster No. 01: #4972

Title: Characteristics of immune gene rearrangements in Chinese Multiple Myeloma patients

First author: He Donghua

Corresponding author: Cai Zhen

All authors: He Donghua, Yang Yang, Yiwei Zhou, Enfan Zhang, Li Yang, Xiaoyan Han, Jingsong He, Cai Zhen

Research Summary:

This study utilized NGS technology to systematically analyze the immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangement characteristics of 79 Chinese patients with multiple myeloma (MM). It was found that the proportion of Ig clones in the initial samples correlated with treatment efficacy. More importantly, the diversity of TCR in peripheral blood was significantly lower in patients than in healthy individuals. Based on this finding, a novel prognostic prediction model with extremely high discrimination (AUC=0.988) was developed, providing a new tool for liquid biopsy and prognostic evaluation in MM.

Poster No. 02: #1929

Title: Timed PD-1 blockade synergizes with IL-7/CCL19 armoring to reverse CAR-T exhaustion in PD-L1-high large B-cell lymphoma

First author: L. Sheng

Corresponding Author: C. Zhang

All Authors: L. Sheng, W. Lei, G. Wu, Y. Wang, Y. Liu, S. Wang, D. Zhou, P. Zhang, H. Xu, S. Tang, T. Lu, Z. Mu, X. Yue, K. Liang, N. Qian, C. Zhang

Research Summary:

This study addresses the issue of CAR-T cell exhaustion in PD-L1-high large B-cell lymphoma by proposing a novel combinatorial therapeutic strategy: the use of 'armored' CAR-T cells expressing IL-7/CCL19 in conjunction with timed PD-1 blockade. Experimental results demonstrate that this combination effectively reverses CAR-T cell exhaustion, significantly enhancing their proliferation, persistence, and anti-tumor functionality, offering a new paradigm for overcoming tumor immune-suppressive microenvironments.

Poster Number: 03#5778

Title: Targeted capture sequencing reveals driver mutations and makes it possible to construct an accurate prognostic model for multiple myeloma

First author: Y. Yang

Corresponding Author: Z. Cai

All Authors: Y. Yang, D. He, J. Zhang, Y. Nie, Y. Hong, Z. Cai

Research Summary:

This study performed driver mutation analysis on 101 newly diagnosed multiple myeloma (MM) patients using targeted capture sequencing. Based on high-frequency mutation profiles such as KRAS, NRAS, and TP53, a precise individualized prognostic risk model was developed. This model demonstrates excellent performance in predicting high-risk patients and significantly outperforms traditional staging systems, providing crucial support for precision diagnosis and treatment of MM.

During the conference, our team also engaged in face-to-face professional exchanges with several top domestic scholars to jointly discuss the clinical implications and future directions of the research findings.

Looking ahead: Continued dedication and collaborative progress

Although ASH 2025 has concluded, the pace of exploration and innovation in hematology continues unabated. KSL Diagnostics will continue to leverage its technical expertise and network in specialized hematology diagnostics to deepen international cooperation and promote the close integration of precision diagnostic technologies with clinical needs.

We thank all global partners who visited our booth and extended their support and trust. Looking ahead, we look forward to continuing our collaboration to advance progress in the field of hematology, delivering precise and efficient diagnostics and services to more patients.

393K Views